A randomised, single-blind bridging study evaluating the immunogenicity and safety of an inactivated trivalent influenza HA vaccine [FluBio] in adolescents and adults

Trial Profile

A randomised, single-blind bridging study evaluating the immunogenicity and safety of an inactivated trivalent influenza HA vaccine [FluBio] in adolescents and adults

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 May 2014

At a glance

  • Drugs Influenza HA vaccine (Flubio) (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top